BioCatalystWatch
GLUEWorkspace / GLUE / OverviewCompany library
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. (GLUE)

Website

Price
Market cap
Next catalystQ4 2026; proposed trial design subject to FDA reviewMRT-8102 — GEMINI-1 · Trial initiationCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

MRT-2359

GSPT1

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

MRT-8102

NEK7

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

MRT-8102

NEK7

PreINDP1P3FilingApproved
Upcoming / outlook

MRT-51443

CDK2

PreINDP1P2P3FilingApproved
MRT-2359

GSPT1

PreINDP1P2P3FilingApproved
Upcoming / outlook

MRT-8102

NEK7

PreINDP1P3FilingApproved
Upcoming / outlook

MRT-55811

Cyclin E1 (CCNE1)

PreINDP1P2P3FilingApproved
Upcoming / outlook

CDK2 and/or cyclin E1-directed MGD

CDK2 × Cyclin E1 (CCNE1)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

CDK2 and/or cyclin E1-directed MGD

CDK2 × Cyclin E1 (CCNE1)

PreINDP1P2P3FilingApproved
Upcoming / outlook

MRT-8102

NEK7

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

MRT-2359

GSPT1

PreINDP1P2P3FilingApproved
Upcoming / outlook

MRT-8102

NEK7

PreINDP1P3FilingApproved
Upcoming / outlook

MRT-8102

NEK7

PreINDP1P3FilingApproved
Upcoming / outlook

Other pipelines

MRT-8102

NEK7

PreINDP1P2P3FilingApproved
MRT-8102

NEK7

CDK2-directed MGD

CDK2

Upcoming / outlook

CCNE1-directed MGD

CCNE1 (Cyclin E1)

Upcoming / outlook

MRT-9347

NEK7

Upcoming / outlook

MRT-9643

CDK2

PreINDP1P2P3FilingApproved

Partner / License out

VAV1

PreINDP1P2P3FilingApproved

VAV1

VAV1

VAV1

History / paused

MRT-2359

GSPT1

PreINDP1P2P3FilingApproved
MRT-8102

NEK7

PreINDP1P2P3FilingApproved
MRT-2359

GSPT1

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

GLUE PR & News

PR & News

GLUE SEC archive